These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 34211836)

  • 1. The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer.
    Crombet Ramos T; Santos Morales O; Dy GK; León Monzón K; Lage Dávila A
    Front Oncol; 2021; 11():639745. PubMed ID: 34211836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.
    Saavedra D; Crombet T
    Front Immunol; 2017; 8():269. PubMed ID: 28348561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of CIMAvax-EGF administered in community polyclinics.
    Ortiz Carrodeguas RA; Lorenzo Monteagudo G; Guerra Chaviano PP; Álvarez Montané I; Salomón Saldívar EE; Lobaina Lambert L; Camacho Sosa K; Bermúdez Pino R; Blanco Mustelier P; Valdés Rodríguez E; González Piloto S; Guerra de la Vega A; Valdés Sánchez L; Montes De Santis A; Parra Zabala J; Viada González C; Calvo Aguilera N; Saavedra Hernández D; Santos Morales O; Crombet Ramos T
    Front Oncol; 2023; 13():1287902. PubMed ID: 38304035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario.
    Flores Vega YI; Páramo González DL; Alsina Sarmiento SC; Alsina Tul LE; Inguanzo Valdés IB; Rodríguez Machado J; Elejalde Larrinaga Á; Flores Rodríguez JE; Lamadrid García J; Corrales Otero D; Ropero Toirac R; Crombet Ramos T; Gracia Medina EA
    J Cancer; 2023; 14(5):874-879. PubMed ID: 37056397
    [No Abstract]   [Full Text] [Related]  

  • 5. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
    Rodriguez PC; Popa X; Martínez O; Mendoza S; Santiesteban E; Crespo T; Amador RM; Fleytas R; Acosta SC; Otero Y; Romero GN; de la Torre A; Cala M; Arzuaga L; Vello L; Reyes D; Futiel N; Sabates T; Catala M; Flores YI; Garcia B; Viada C; Lorenzo-Luaces P; Marrero MA; Alonso L; Parra J; Aguilera N; Pomares Y; Sierra P; Rodríguez G; Mazorra Z; Lage A; Crombet T; Neninger E
    Clin Cancer Res; 2016 Aug; 22(15):3782-90. PubMed ID: 26927662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.
    Evans R; Lee K; Wallace PK; Reid M; Muhitch J; Dozier A; Mesa C; Luaces PL; Santos-Morales O; Groman A; Cedeno C; Cinquino A; Fisher DT; Puzanov I; Opyrchal M; Fountzilas C; Dai T; Ernstoff M; Attwood K; Hutson A; Johnson C; Mazorra Z; Saavedra D; Leon K; Lage A; Crombet T; Dy GK
    Front Oncol; 2022; 12():958043. PubMed ID: 35992783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
    Tagliamento M; Rijavec E; Barletta G; Biello F; Rossi G; Grossi F; Genova C
    Expert Opin Biol Ther; 2018 Jul; 18(7):829-835. PubMed ID: 29936901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
    Saavedra D; Neninger E; Rodriguez C; Viada C; Mazorra Z; Lage A; Crombet T
    Semin Oncol; 2018 Jan; 45(1-2):34-40. PubMed ID: 30318082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.
    Rodríguez PC; Rodríguez G; González G; Lage A
    MEDICC Rev; 2010; 12(1):17-23. PubMed ID: 20387330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
    Popa X; García B; Fuentes KP; Huerta V; Alvarez K; Viada CE; Neninger E; Rodríguez PC; González Z; González A; Crombet T; Mazorra Z
    Oncoimmunology; 2020 May; 9(1):1762465. PubMed ID: 32923124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
    Crombet Ramos T; Rodríguez PC; Neninger Vinageras E; Garcia Verdecia B; Lage Davila A
    Expert Rev Vaccines; 2015; 14(10):1303-11. PubMed ID: 26295963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
    Goss GD; Spaans JN
    Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.
    Rodriguez PC; Neninger E; García B; Popa X; Viada C; Luaces P; González G; Lage A; Montero E; Crombet T
    J Immune Based Ther Vaccines; 2011 Oct; 9():7. PubMed ID: 22024351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
    Suárez GM; Catalá M; Peña Y; Portela S; Añé-Kourí AL; González A; Lorenzo-Luaces P; Díaz M; Molina MLA; Pereira K; Hernández JC; Ramos R; Reyes MC; Ledón N; Mazorra Z; Crombet T; Lage A; Saavedra D
    Front Oncol; 2022; 12():823287. PubMed ID: 35155258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.
    Lorenzo-Luaces P; Sanchez L; Saavedra D; Crombet T; Van der Elst W; Alonso A; Molenberghs G; Lage A
    BMC Cancer; 2020 Aug; 20(1):772. PubMed ID: 32807114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative Efficacies of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Treatment of Recurrent Non-Small Cell Lung Cancer after Surgery.
    Motono N; Mizoguchi T; Ishikawa M; Iwai S; Iijima Y; Uramoto H
    Oncology; 2024; 102(6):476-483. PubMed ID: 37984347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
    Ruiz R; Hunis B; Raez LE
    Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research Advances in CIMAvax-EGF for Non-small-cell Lung Cancer].
    Zhang JY; Zhu L; Yang HK; Chen F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Jun; 40(3):411-414. PubMed ID: 29978802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.
    Rodríguez-Abreu D; Cobo M; García-Román S; Viteri-Ramírez S; Jordana-Ariza N; García-Peláez B; Reguart N; Aguilar A; Codony-Servat J; Drozdowskyj A; Molina-Vila MA; d'Hondt E; Rosell R
    Lung Cancer; 2022 Feb; 164():8-13. PubMed ID: 34971901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.